Red Light Therapy

Red light therapy's foundation is legitimate: photobiomodulation (PBM) — low-level red (~630-700 nm) and near-infrared (~800-900 nm) light absorbed by cellular chromophores (cytochrome c oxidase in mitochondria above all), producing measurable changes in cellular energetics, signalling and local blood flow — is a documented phenomenon with thousands of papers, decades of laser history (the field began as “low-level laser therapy” in the 1960s), and biological plausibility this collection's pure-pseudoscience files (grounding, homeopathy) never had. The equally documented complication: PBM shows a biphasic dose response — too little light does nothing, the right window does something, and more light can undo or reverse the effect — with outcomes depending on wavelength, irradiance, time, pulsing and tissue depth. That finickiness is the field's honest core problem: trial parameters vary so widely that meta-analyses average incompatible doses, replication is poor, and the consumer market sells devices whose delivered dose at tissue is usually unknown — meaning a buyer can hold real science in their hands and still receive none of it.

Scored by randomised evidence, the defensible niches. Androgenetic (pattern) hair loss: the category's best consumer story — multiple randomised device trials (laser combs, caps) show modest increases in hair density versus sham, enough for FDA clearances and cautious guideline mentions; effects are real, modest, and require indefinite continued use. Skin: small randomised trials support modest improvements in fine wrinkles, skin texture and collagen markers (the basis of the LED-mask economy) and mild-to-moderate acne (blue-red combinations), with dermatology treating office-grade PBM as a legitimate minor tool. Musculoskeletal pain and tendinopathy: a large, messy trial literature with positive meta-analytic signals for short-term pain in some conditions (neck pain, tendinopathies) undermined by dose heterogeneity and blinding limits — plausible adjunct, unsettled science. Oral mucositis in cancer care: the sleeper legitimate use — PBM is guideline-recommended in supportive oncology to prevent and treat chemotherapy- and radiotherapy-induced mucositis, the field's strongest institutional endorsement. Wound healing: promising mechanistically, mixed clinically. That is approximately the list; everything else lives in the next message.

The expansion claims, scored. “Red light melts fat”: body-contouring devices hold clearances on small waist-circumference trials whose clinical meaning is disputed; controlled evidence for meaningful, durable fat loss is absent — the panels heat and the marketing does the rest. Brain enhancement and mood: transcranial PBM has genuinely interesting pilot studies (depression, cognition, TBI) — small, mixed, unreplicated at scale; a research frontier retailed as a finished product, with helmet vendors quoting rodent hippocampi at consumers. Thyroid repair: a couple of small trials in autoimmune thyroiditis anchor an entire influencer subgenre; no guideline anywhere endorses shining light at thyroids in place of monitoring and treatment. Testosterone, “mitochondrial optimisation”, longevity: mechanism talk without outcome trials — the standard biohacking ladder from electron-transport diagrams to lifespan promises. Vision: animal and small human studies on retinal ageing exist alongside the one hard safety rule (never stare into high-power sources). The pattern across all of it is the collection's familiar one: a real phenomenon's vocabulary licensing claims its trials never earned — with the biphasic dose problem quietly guaranteeing that even the true niches may not survive translation to an uncalibrated $99 panel.

The consumer economics deserve their own scoring. “FDA cleared” is the market's load-bearing phrase — clearance (510(k)) means a device is deemed similar to an existing device and safe for its listed use, not that efficacy was proven to drug standards; masks, panels and belts wear the phrase as if it were approval, and marketing copy upgrades wrinkle-clearances into systemic medicine. Dose opacity is the deeper problem: effective PBM depends on delivering specific energy densities to target tissue, consumer devices vary orders of magnitude in output, distance and session guidance, published device parameters often don't match bench measurements, and near-infrared claims from LED panels compete with the physics of skin penetration — so the honest consumer answer to “does this panel work?” is usually “nobody, including the manufacturer, has tested that question”. Safety, credit where due: PBM at consumer intensities is remarkably benign — eyes are the main caution (protect them near high-power panels), photosensitising medications and active skin cancers are standard exclusions, and the field's worst harms are financial. Which frames the purchase decision honestly: low risk, real-but-niche evidence, unverifiable dosing — a recreational gadget with a chance of modest benefit in the supported niches, not an investment in cellular medicine.

Red light is the collection's best teaching case for evaluating a half-real therapy, and the checklist transfers. Ask which indication: PBM is not one claim but dozens — hair, mucositis and skin behave differently from fat, brains and thyroids; a field's best evidence does not transfer across its own claim list. Ask which dose: any source discussing red light without wavelength, irradiance and time is discussing lighting, not medicine — and any device not publishing measured (not theoretical) output has answered your question. Ask sham-controlled or glow-controlled: red light produces warmth, colour and ritual — placebo's favourite ingredients; only sham-device trials count, and they are the minority. Ask who benefits from the systemic story: mask sellers need faces, panel sellers need whole bodies, and the mitochondria-optimisation narrative conveniently requires the largest products. And ask what the boring alternative is: for hair, minoxidil and finasteride have deeper evidence; for skin, retinoids and sunscreen; for pain, exercise therapy; for mood, the treatments with actual trials — red light's honest role is adjunct or preference, never replacement.

If you want to try it for the supported niches: pattern hair loss (cleared cap/comb devices, expect modest density gains after months, continued use required), skin texture and mild acne (masks and office treatments — modest, real, cosmetic-tier), or as a pain adjunct alongside actual rehabilitation — reasonable, low-risk purchases if the money is discretionary; protect your eyes, skip it over active cancers and with photosensitising drugs, and give any use a defined trial period with a stopping rule. If you are being sold fat loss, brain optimisation, thyroid healing, hormone or longevity effects: the trials are not there — file it with the biohacking economy and keep the money. If you have cancer treatment ahead: ask the oncology team about PBM for mucositis — the one place this field is guideline medicine. And the transferable rule: in dose-dependent therapies, a device that cannot state its delivered dose cannot claim its literature — “red light” is a category of physics, not a guarantee of biology.